Melanoma & Skin Oncology Research

The Skin and Melanoma Site Group at Princess Margaret aims to continuously advance the frontiers of clinical and translational research in our field to provide cutting-edge treatment and management in medical, surgical and radiation oncology.

Our group is establishing molecular genetic tests, such as fluorescent in situ hybridization (FISH), which will help pathologists in the differential diagnosis of borderline melanocytic lesions, including atypical Spitzoid tumours. We are also developing tissue microarrays for melanoma, sebaceous carcinoma and Merkel cell carcinoma.

Our melanoma database tracks patient outcomes so we can better understand the nature and complexity of melanomas and how treatments affect tumour types. In the long term this database will inform and advance patient assessment and treatment planning to improve patient outcomes.

The significant clinical trials work we do includes testing therapies directed against B-RAF, N-RAS and C-KIT mutations, as well as novel targets in metastatic melanomas.

Open Clinical Trials

NCT and Other Names

Title

Principal Investigator

Disease Location


Melanoma
NCT05665595 7684A-010, MK-7684A-010,KEYVIBE-010,2022-501417-31-00,jRCT2031230099,U1111-1280-3661	A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)	Dr. Marcus Butler	Melanoma
NCT05061134 D533AC00001, 2024-512378-91-00,2021-001722-21	A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition	Dr. Marcus Butler	Melanoma
NCT05081609 ASND0029	A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies	Dr. Sam Saibil	Melanoma
NCT06377111 PANTHEON-IO	A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma	Dr. Sam Saibil	Melanoma
NCT06246916 R3767-ONC-22122	A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)	Dr. Marcus Butler	Melanoma
NCT06190951 R3767-ONC-2208, 2022-502825-17-00	A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma	Dr. Marcus Butler	Melanoma
NCT05608291 R3767-ONC-2055, 2022-501576-25-00	A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery	Dr. Marcus Butler	Melanoma
NCT06319196 Clear Me	Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma	Dr. Anna Spreafico	Melanoma
NCT05352672 R3767-ONC-2011, 2021-004453-23,2023-505772-30-00	Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma	Dr. Marcus Butler	Melanoma
NCT02821013 ME13, UQ-QMP-0001	Duration of Anti-PD-1 Therapy in Metastatic Melanoma	Dr. Marcus Butler	Melanoma
NCT06112314 IMC-F106C-301, 2023-505306-42	IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)	Dr. Marcus Butler	Melanoma
NCT06623461 ME17	LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma	Dr. Marcus Butler	Melanoma
NCT03860883 02.18	Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma	Dr. Alexandra Easson	Melanoma
NCT04830124 ALKS 4230-006	Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6	Dr. Anna Spreafico	Melanoma
NCT05727904 IOV-MEL-301, TILVANCE-301,TILVANCE	Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.	Dr. Marcus Butler	Melanoma
NCT05549297 IMCgp100-203	Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)	Dr. Marcus Butler	Melanoma
NCT05111574 NCI-2021-11794, NCI-2021-11794,A091903,A091903,U10CA180821	Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery	Dr. Marcus Butler	Melanoma
Merkel Cell Carcinoma
NCT05947500 NCI-2023-05259, NCI-2023-05259,10592,10592,P30CA015704	Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial	Dr. Sam Saibil	Merkel Cell Carcinoma
Other
NCT05323253 CTP-SCC-03	A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma	Dr. Philip Wong	Other
NCT06171750 ANK-101-001	Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors	Dr. Marcus Butler	Other

To refer a patient to a clinical trial, complete a new patient referral form. Learn more about the Princess Margaret referral process »

For patients: Are you considering taking part in a clinical trial? Learn more about how and why clinical trials are done and what you can expect if you decide to take part in a trial »

https://www.uhn.ca/PrincessMargaret/Education/Continuing_Education_Programs/Pages/continuing_education_programs.aspx

Last reviewed: 4/30/2023

Last modified: 11/8/2024 11:44 AM